LGND:NSD-Ligand Pharmaceuticals Incorporated (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 85.29

Change

+1.22 (+1.45)%

Market Cap

USD 2.23B

Volume

0.16M

Analyst Target

USD 191.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ligand Pharmaceuticals Inc is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ALNY Alnylam Pharmaceuticals Inc

-3.20 (-1.12%)

USD 36.83B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B

ETFs Containing LGND

BACK:LSE 0.00 % 0.00 %

N/A

N/A
VALX 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.42% 70% C- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.42% 70% C- 81% B-
Trailing 12 Months  
Capital Gain 10.57% 69% C- 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.57% 69% C- 60% D-
Trailing 5 Years  
Capital Gain -26.52% 66% D+ 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.52% 66% D+ 33% F
Average Annual (5 Year Horizon)  
Capital Gain -0.97% 57% F 43% F
Dividend Return -0.97% 57% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.30% 58% F 35% F
Risk Adjusted Return -2.00% 56% F 39% F
Market Capitalization 2.23B 85% B 75% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 357.70 25% 40%
Price/Book Ratio 2.06 61% 47%
Price / Cash Flow Ratio 25.56 3% 11%
Price/Free Cash Flow Ratio 12.78 3% 21%
Management Effectiveness  
Return on Equity 8.29% 96% 73%
Return on Invested Capital 0.00% 86% 60%
Return on Assets 0.79% 96% 67%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector